Sign In
Buy JAZZ
$230.93
+4.81 (+2.13%)
At Close: Jun 03, 2026
Jazz Pharmaceuticals to Present Data at 2022 ASH Meeting Showcasing Commitment to Advancing Oncology Research
10:43am, Thursday, 03'rd Nov 2022
Key data includes results for intravenous administration of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Patients DUBLIN ,
4 High Earnings Yield Picks That You Shouldn't Ignore
10:32am, Friday, 28'th Oct 2022
ALB, CVX, JAZZ and CMI are a few high earnings yield value picks with solid upside potential.
Jazz Pharmaceuticals' Deal With Zymeworks Offers Good Reward-Risk Ratio
09:02am, Wednesday, 26'th Oct 2022
Jazz Pharmaceuticals will pay $50 million upfront for an option to in-license Zymeworks' zanidatamab. Zymeworks carries most of the risk until Jazz opts in. If the deal goes through, Zymeworks would b
JAZZ or ZTS: Which Is the Better Value Stock Right Now?
12:47pm, Thursday, 20'th Oct 2022
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
5 Stocks to Bet on in an Innovation-Driven Drug Industry
12:02pm, Thursday, 20'th Oct 2022
Innovation is expected continue driving growth in the Medical-Drugs industry in 2023. JAZZ, CPRX, AERI, LRMR and FUSN may prove to be good additions to one's portfolio.
Zymeworks, Jazz agree to licensing deal for cancer drug
08:38am, Wednesday, 19'th Oct 2022
Shares of Zymeworks Inc. ZYME, -2.43% gained 8.4% in premarket trading on Wednesday after the company announced a licensing deal with Jazz Pharmaceuticals plc JAZZ, -0.41% for its cancer drug, zanidat
Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab
06:07am, Wednesday, 19'th Oct 2022
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics,
Here's Why You Should Consider Investing in JAZZ Stock Now
12:03pm, Monday, 17'th Oct 2022
JAZZ's new drugs like Xywav, Rylaze and Zepzelca, along with the recently-acquired drugs, are expected to generate 65% of product revenues in 2022.
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
11:17am, Friday, 14'th Oct 2022
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
JAZZ vs. CTLT: Which Stock Is the Better Value Option?
12:47pm, Tuesday, 04'th Oct 2022
JAZZ vs. CTLT: Which Stock Is the Better Value Option?
Got $2,000? Buy These 2 Bear Market-Beating Growth Stocks
10:37am, Sunday, 02'nd Oct 2022
Neither company has any reason to worry about a recession either.
Top Medical Marijuana Stocks To Buy? 2 Big Pharma Plays In Cannabis
11:30am, Thursday, 22'nd Sep 2022
Could These Be Good Long Term Investments Into Cannabis? The post Top Medical Marijuana Stocks To Buy? 2 Big Pharma Plays In Cannabis appeared first on Marijuana Stocks | Cannabis Investments and News
Jazz Pharmaceuticals to Present Advancements in Sleep Medicine at Psych Congress 2022
04:30pm, Thursday, 15'th Sep 2022
Seven abstracts emphasize Jazz's leadership in neuroscience and commitment to ongoing innovation DUBLIN , Sept. 15, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that th
3 Top Pot Stocks to Watch in September
07:00am, Thursday, 15'th Sep 2022
All three of these cannabis-related stocks turned profits last quarter and have had strong revenue growth.
Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Value Stock: Should You Buy?
11:13am, Wednesday, 14'th Sep 2022
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
